Phase I cancer trials methodology;Méthodologie des essais de phase I en cancérologie

Bulletin du Cancer

Volumn 94, Issue 11, 2007, Pages 943-951

  Le Tourneau, Christophe ^a   Faivre, Sandrine ^a   Raymond, Eric ^a   Diéras, Véronique ^b  

^a BEAUJON HOSPITAL   (France)

^b INSTITUT CURIE   (France)

Author keywords

Accelerated titration designs; Clinical trial; Continual reassessment method; Escalation with overdose control; Fibonacci escalation; Phase I

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOTHERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, BIOLOGICAL; NEOPLASMS; PATIENT CARE TEAM; PATIENT SELECTION;

EID: 37349040201     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0493     Document Type: Article

References (27)

1. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, et al. Risks and benefits of phase I oncology trials, 1991 through 2002. N Engl J Med 2005 ; 352 : 895-904.
2. Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmor WF. Improvement of cis-dichiorodiamine platinum (NSC 119875): therapeutic index in an animal model. Cancer 1977 ; 39 : 1357-61.
3. Faivre S, Chieze S, Delbaldo C, Ady-Vago N, Guzman C, Lopez-Lazaro L, et al. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol 2005 ; 23 : 7871-80.
4. Daugherty C, Ratain MJ, Grochowski E, Stocking C, Kodish E, Mick R, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 1995 ; 13 : 1062-72.
5. Von Hoff DD, Turner J. Response rates, duration of response and dose response effects in phase I trials of antineoplastics. Invest New Drugs 1991 ; 9 : 115-22.
6. Collins JM, Zaharko DS, Dedrick RL, Chabner BA. Potential role for preclinical pharmacology in phase I trials. Cancer Treat Rep 1986 ; 70 : 73-80.
7. Collins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase I trials based upon preclinical development. J Natl Cancer Inst 1990 ; 82 : 1321-6.
8. Newell DR. Pharmacologically based phase I trials in cancer chemotherapy. Hematol Oncol Clin North Am 1994 ; 8 : 257-75.
9. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials : Efficient dose escalations with overdose control. Stat Med 1998 ; 17 : 1103-20.
10. Rogatko A, Babb J. Escalation With Overdose Control (EWOC). www.fccc.edu/users/rogatko.
11. O'Quigley J, Pepe M, Fisher L. Continual reassessment method : A practical design for phase I clinical trials in cancer. Biometrics 1990 ; 46 : 33-48.
12. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvments in the continual reassessment method for phase I studies. Stat Med 1995 ; 14 : 1149-61.
13. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997 ; 89 : 1138-47.
14. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000 ; 18 : 684-92.
15. Balis FM, Holcenberg JS, Bleyer WA. Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 1983 ; 8 : 202-32.
16. Agulnik M, Oza AM, Pond GR, Siu LL. Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol 2006 ; 24 : 4801-7.
17. Ollivier L, Leclere J, Thiesse P, Di Stefano D, Vincent C. Measurement of tumour response to cancer treatment : morphologic imaging role. Bull Cancer 2007 ; 94 : 171-7.
18. Cachin F, Kelly A, Maublant J. [Evaluation of the therapeutic response : role of isotopic imaging. Bull Cancer 2006 ; 93 : 1191-9.
19. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non cytotoxic agents: theory and practice. J Natl Cancer Inst 2004 ; 96 : 990-7.
20. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 ; 349 : 427-34.
21. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 ; 344 : 783-92.
22. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 ; 350 : 2335-42.
23. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer : a phase III trial : Intact 2. J Clin Oncol 2004 ; 22 : 785-94.
24. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer : a phase III trial : Intact 1. J Clin Oncol 2004 ; 22 : 777-84.
25. Lynch TJ, Raju R, Lind M, Riviere A, Gatzemeier U, Drorr A, et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (Isis 3521) in patients with advanced NSCLC : initial report. Proc ASCO 2003 ; 22 : 623.
26. Van Custem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2(904 ; 22 : 1430-8.
27. Kramar A, Kachmar T, Hannoun-Levi JM. Increasing the quality of clinical trials in oncology : an important challenge. Bull Cancer 2003 ; 90 : 919-23.